Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE

December 15, 2023

https://www.globenewswire.com/news-release/2023/12/06/2791632/0/en/Optinose-Announces-3-Month-Extension-of-FDA-Review-Period-for-the-Supplemental-New-Drug-Application-for-XHANCE.html

The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis

Read more at globenewswire.com

Related news for (OPTN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.